Harrow (NASDAQ:HROW) Stock Price Down 4.9% – Should You Sell?

Harrow, Inc. (NASDAQ:HROW) shares dropped 4.9% during mid-day trading on Tuesday . The company traded as low as $39.51 and last traded at $39.79. Approximately 75,863 shares were traded during mid-day trading, a decline of 85% from the average daily volume of 508,519 shares. The stock had previously closed at $41.86.

Wall Street Analyst Weigh In

HROW has been the subject of a number of recent analyst reports. Lake Street Capital increased their target price on shares of Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, October 4th. Craig Hallum increased their target price on shares of Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, October 4th. Finally, B. Riley decreased their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research report on Wednesday.

Harrow Price Performance

The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The stock’s fifty day simple moving average is $47.32 and its two-hundred day simple moving average is $35.06.

Institutional Trading of Harrow

Hedge funds have recently bought and sold shares of the company. Quest Partners LLC purchased a new stake in Harrow during the third quarter valued at about $29,000. nVerses Capital LLC purchased a new stake in Harrow during the second quarter valued at about $33,000. Allspring Global Investments Holdings LLC lifted its stake in Harrow by 2,730.7% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock valued at $44,000 after buying an additional 2,048 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Harrow by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock valued at $57,000 after buying an additional 227 shares in the last quarter. Finally, Hills Bank & Trust Co purchased a new stake in Harrow during the third quarter valued at about $107,000. 72.76% of the stock is owned by hedge funds and other institutional investors.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.